Health Catalyst Is Maintained at Outperform by Evercore ISI Group
Evercore Maintains Health Catalyst(HCAT.US) With Buy Rating, Raises Target Price to $10
Health Catalyst Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Health Catalyst, Maintains $16 Price Target
CCORF Maintains Health Catalyst(HCAT.US) With Buy Rating, Maintains Target Price $11
Health Catalyst Price Target Raised to $13.00/Share From $10.00 by JP Morgan
J.P. Morgan Maintains Health Catalyst(HCAT.US) With Buy Rating, Raises Target Price to $13
CCORF Maintains Health Catalyst(HCAT.US) With Buy Rating, Maintains Target Price $11
Buy Rating Affirmed on Health Catalyst Amid Positive Growth and Strategic Initiatives
Health Catalyst Analyst Ratings
Piper Sandler Maintains Overweight on Health Catalyst, Lowers Price Target to $11
Piper Sandler Maintains Health Catalyst(HCAT.US) With Buy Rating, Cuts Target Price to $11
Health Catalyst Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Health Catalyst, Maintains $16 Price Target
Barclays Maintains Health Catalyst(HCAT.US) With Buy Rating, Maintains Target Price $14
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Progyny (PGNY) and Health Catalyst (HCAT)
Health Catalyst (HCAT) Receives a Buy From Barclays
Health Catalyst Price Target Maintained With a $16.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Remains a Buy on Health Catalyst (HCAT)
Health Catalyst Analyst Ratings